Prodigiosin inhibits bacterial growth and virulence factors as a potential physiological response to interspecies competition

• Published in: PloS one Vol. 16; no. 6; p. e0253445
• Main Authors: Yip, Chee-Hoo, Mahalingam, Sobina, Wan, Kiew-Lian, Nathan, Sheila
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 23.06.2021; Public Library of Science (PLoS)
• Subjects: Absorption spectra; Analysis; Antiinfectives and antibacterials; Antimicrobial activity; Bacteria; Biofilms; Biology and Life Sciences; Biotechnology; Cell cycle; Chromatography; Competition; Drug resistance; E coli; Glycerol; Gram-positive bacteria; Growth; High performance liquid chromatography; Laboratories; Liquid chromatography; Medicine and Health Sciences; Methicillin; Microorganisms; Minimum inhibitory concentration; Nocardia corallina; Pathogens; Physiological effects; Physiology; Prodigiosin; Protease; Proteinase; Pseudomonas aeruginosa; Salmonella; Soil bacteria; Soil water; Spectrophotometry; Staphylococcus aureus; Staphylococcus infections; Surface water; Virulence; Virulence (Microbiology); Virulence factors; Malaysia; Selangor Malaysia; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0253445

Prodigiosin, a red linear tripyrrole pigment, has long been recognised for its antimicrobial property. However, the physiological contribution of prodigiosin to the survival of its producing hosts still remains undefined. Hence, the aim of this study was to investigate the biological role of prodigiosin from Serratia marcescens, particularly in microbial competition through its antimicrobial activity, towards the growth and secreted virulence factors of four clinical pathogenic bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa) as well as Staphylococcus aureus and Escherichia coli. Prodigiosin was first extracted from S. marcescens and its purity confirmed by absorption spectrum, high performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrophotometry (LC-MS/MS). The extracted prodigiosin was antagonistic towards all the tested bacteria. A disc-diffusion assay showed that prodigiosin is more selective towards Gram-positive bacteria and inhibited the growth of MRSA, S. aureus and E. faecalis and Gram-negative E. coli. A minimum inhibitory concentration of 10 [mu]g/[mu]L of prodigiosin was required to inhibit the growth of S. aureus, E. coli and E. faecalis whereas > 10 [mu]g/[mu]L was required to inhibit MRSA growth. We further assessed the effect of prodigiosin towards bacterial virulence factors such as haemolysin and production of protease as well as on biofilm formation. Prodigiosin did not inhibit haemolysis activity of clinically associated bacteria but was able to reduce protease activity for MRSA, E. coli and E. faecalis as well as decrease E. faecalis, Salmonella Typhimurium and E. coli biofilm formation. Results of this study show that in addition to its role in inhibiting bacterial growth, prodigiosin also inhibits the bacterial virulence factor protease production and biofilm formation, two strategies employed by bacteria in response to microbial competition. As clinical pathogens were more resistant to prodigiosin, we propose that prodigiosin is physiologically important for S. marcescens to compete against other bacteria in its natural soil and surface water environments.